In spite of the relevance of (BRCA2) breast cancer gene 2 which gene for suppression of cancer in hereditary malignancies of breast and ovarian is well recognized. The discovery of EMSY, a recent protein binding to BRCA2, as a possible Oncogene implies that the (breast cancer gene 2) system has a role in non- hereditary (sporadic) malignancies. The study's aim is determining the attendance of EMSY mutation in breast cancer. 60 patients diagnosed with breast cancer, classified according to the genotype, age, family history, aggressive type of breast cancer and other types of tumors associated with EMSY gene. This study was based in PCR sequencing to determine the attendance of EMSY mutation. Incidence of breast cancer occurred in 37 % patients aged 25-40 years old, while incidence of metastatic breast cancer was 53% of cases, incidence of linkage of EMSY gene to BRACA2 in cases of breast cancer was: 73%, incidence of linkage of EMSY gene to BRACA2 in cases of breast cancer was: 43% with positive family history of breast cancer , incidence of linkage of EMSY gene to BRACA2 in cases of stage 4 breast cancer was: 68.2 and incidence of linkage of EMSY gene to BRACA2 in cases of other types of cancer was: 22.7% with ovarian cancer. The EMSY gene has been linked to a poor outcome in cases of metastatic breast cancer. To confirm that EMSY is over presented in primary breast and ovarian tumors, more evidence is required.